Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy

Abstract

RNA interference (RNAi) is a gene regulation mechanism initiated by RNA molecules that enables sequence-specific gene silencing by promoting degradation of specific mRNAs. Molecular therapy using small interfering RNA (siRNA) has shown great therapeutic potential for diseases caused by abnormal gene overexpression or mutation. The major challenges to application of siRNA therapeutics include the stability and effective delivery of siRNA in vivo. Important progress in nanotechnology has led to the development of efficient siRNA delivery systems. In this review, the authors discuss recent advances in nanoparticle-mediated siRNA delivery and the application of siRNA in clinical trials for cancer therapy. This review will also offer perspectives on future applications of siRNA therapeutics.

Medicated Nanoparticle for Gene Delivery

“…and inorganic systems (magnetic nanoparticles, quantum dots, carbon nanotubes, gold nanoparticles (GNPs), etc.) [45].…”

Strategist PLGA Nano-capsules to Deliver siRNA for Inhibition of Carcinoma and Neuroblastoma Cell Lines by Knockdown of MYC Proto-oncogene using CPPs and PNA

“…Also post-injection, NP-siRNA conjugates must navigate through the circulatory system, avoiding kidney filtration, uptake by phagocytosis, aggregation with serum proteins and escape enzymatic degradation [25]. Hence, there is a need to formulate siRNAencapsulated NPs that can target the nucleus of cancerous tissue [25][26][27].…”

RNAi-based Cancer Therapeutics: Are we there yet?

“…In the last decade or so, the RNA interference (RNAi) technology, mediated primarily by small interfering RNA (siRNAs) and micro RNA (miRNAs) has emerged as one of the most promising strategies for cancer therapeutics [6][7][8], primarily due to its high specificity, precise mechanism of action and potency [9]. The strategy is also advantageous in terms of its capability to target multiple oncogenes simultaneously.…”